For example, RU-486, a GCR antagonist, is used for the treatment of several cancers, including breast, ovarian, and prostate, and glaucoma [57], and it has been shown to sensitize renal carcinoma cells to TRAIL-induced apoptosis through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2 [58]. This evidence concerns the gene BCL2 and renal carcinoma.